- |||||||||| Capvaxive (V116) / Merck (MSD), Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Biomarker, Clinical, Review, Journal: Establishing a new human pneumococcal standard reference serum, MPRSS-01. (Pubmed Central) - Jan 28, 2025
With the development of next-generation PCVs, a new S. pneumoniae reference serum standard was needed to include serotypes beyond the existing 24 in 007sp. In this study, antibody concentrations to 33 pneumococcal serotypes were assigned in a new Merck Pneumococcal Reference Serum Standard (MPRSS-01) using the pneumococcal electrochemiluminescence assay, enabling V116 to maintain the link to the historical human pneumococcal standard reference serum while utilizing the new human pneumococcal reference serum.
- |||||||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion date, Trial primary completion date: MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - Jan 8, 2025
P=N/A, N=45, Recruiting,
This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Trial primary completion date: Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 3, 2025
P2, N=80, Recruiting,
Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026 Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open: Clinical Trial of PCV24 in Adults (clinicaltrials.gov) - Dec 26, 2024
P1, N=168, Recruiting,
Trial primary completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting
- |||||||||| inactivated whole-cell pneumococcal vaccine (Gamma-PN3) / Gamma Vaccines
Trial completion: Extension Safety and Immunogenicity Study of GPNV-001 (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=60, Completed,
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns () - Dec 7, 2024 - Abstract #ASH2024ASH_9208;
All centers offered both teclistamab and talquetamab, and 7 also used elranatamab...Other vaccines were used less frequently : Prevnar 20 (33%), Pentavalent (DPT, Hep B, H.influenzae) (27%), Hep B virus (27%), RZV (27%), MCV4 (20%), Pneumovax 23 (20%), HPV (20%), MMR live (20%) and VZV live (6%)...While there are limitations in the generalizability of these practices, these findings demonstrate several areas with varying clinical practices across USMIRC centers. Further studies are needed to correlate these practices with infection rates and to allow development of consensus guidelines for both academic and community centers.
- |||||||||| Capvaxive (V116) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Na (Pubmed Central) - Nov 15, 2024
Further studies are needed to correlate these practices with infection rates and to allow development of consensus guidelines for both academic and community centers. These results demonstrated that using V116 in adults aged???65
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - Nov 8, 2024
P2, N=90, Recruiting,
These results demonstrated that using V116 in adults aged???65 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Rituxan (rituximab) / Roche
Immune Reconstitution and Readiness for Vaccination after Pediatric Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3201;
Patient characteristics and baseline HCT factors assessed for association with readiness for revaccination at 8 months included : age, sex, malignancy type, stem cell source, graft manipulation, GVHD status, and receipt of rituximab...This data will inform immune response based re-immunization protocols and equip clinicians to manage expectations about vaccine timing for patients and caregivers. Further studies are needed in this clinical arena with larger sample sizes where detecting significant associations between potential covariates and vaccine readiness may be more apparent.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Journal: Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population. (Pubmed Central) - Oct 19, 2024
Individuals receiving PCV as their primary vaccine required fewer total pneumococcal vaccine doses to achieve WHO?8/12PnPS and experienced greater duration of time above this threshold than those with PPV as the primary vaccine. However, the median longevity of both vaccine responses was relatively short, which supports the use of ongoing booster doses using high-valency glycoconjugate vaccines to sustain WHO?8/12PnPS threshold antibody levels.
- |||||||||| Capvaxive (V116) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Journal: Capvaxive - A 21-valent pneumococcal conjugate vaccine. (Pubmed Central) - Oct 9, 2024
However, the median longevity of both vaccine responses was relatively short, which supports the use of ongoing booster doses using high-valency glycoconjugate vaccines to sustain WHO?8/12PnPS threshold antibody levels. No abstract available
- |||||||||| SYMMETRICAL DRUG-RELATED INTERTRIGINOUS AND FLEXURAL EXANTHEMA (SDRIFE) FOLLOWING FIRST ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT (Monitor 2; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_737;
Workup revealed decreased immunoglobulin G (IgG) of 466 mg/dl, absent titers to streptococcus pneumoniae and haemophilus influenza without improvement following Pneumovax challenge...Emergency room evaluation with Dermatology evaluation revealed normal blood counts and chemistries with elevated C-reactive protein suggestive of a diagnosis of SDRIFE that was treated with a prednisone taper...This case describes the second reported SDRIFE resulting from IVIG and is the first to describe successful avoidance of exanthem on subsequent exposures. With the change to Gamunex from Privigen formulation, the patient has tolerated the recommended treatment without further complications and remains infection free.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Cresemba (isavuconazonium sulfate) / Astellas, Basilea
PITHOMYCE; A RARE CAUSE OF INVASIVE PULMONARY DISEASE (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6327;
Treatment with azoles such as voriconazole can be used to sufficiently treat such infections. In patients who are immunocompromised with evidence of invasive pulmonary disease for whom routine cultures are negative, use of non-culture dependent techniques for recovery of fastidious or extremely slow growing organisms should be considered.
- |||||||||| inactivated whole-cell pneumococcal vaccine (Gamma-PN3) / Gamma Vaccines
Trial completion, Pneumococcal vaccines: Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. (clinicaltrials.gov) - Sep 4, 2024
P1, N=118, Completed,
In patients who are immunocompromised with evidence of invasive pulmonary disease for whom routine cultures are negative, use of non-culture dependent techniques for recovery of fastidious or extremely slow growing organisms should be considered. Recruiting --> Completed
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Engaging the CF care team through re-establishing a routine team meeting structure () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1110;
This practice challenged the program coordinator to exercise leadership, facilitate communication, challenge team members, and encourage teamwork. Future directions for improvement include rotating meeting roles, incorporating Partnership Enhancement Program principles, and challenging sub-committees to meet routinely and give reports at team meetings as appropriate.
- |||||||||| Trial completion date, Trial primary completion date: Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - Aug 26, 2024
P4, N=500, Recruiting,
Future directions for improvement include rotating meeting roles, incorporating Partnership Enhancement Program principles, and challenging sub-committees to meet routinely and give reports at team meetings as appropriate. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion: Polysaccharide Antibody Response Study (clinicaltrials.gov) - Jul 14, 2024
P4, N=200, Completed,
Aims & This is a prospective, multicenter, randomized study comparing two vaccine regimens: intensified vaccine strategy (Prevenar13 Unknown status --> Completed
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P1 trial: Clinical Trial of PCV24 in Adults (clinicaltrials.gov) - Jun 25, 2024
P1, N=168, Not yet recruiting,
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
NO WANING OF PNEUMOCOCCAL VACCINE RESPONSES OVER TIME IN PEOPLE WITH INFLAMMATORY ARTHRITIS: FINDINGS FROM A SINGLE CENTRE COHORT () - May 29, 2024 - Abstract #EULAR2024EULAR_4516;
This was a single centre, retrospective cohort study of individuals with rheumatoid arthritis, psoriatic arthritis or axial spondylarthritis who had previously received the PPSV23 polysaccharide pneumococcal vaccine (Pneumovax)... We have demonstrated that antibody titres following do not appear to wane over time, and it appears more critical to focus on maximising the initial vaccine response, which is known to be diminished in this patient population.
- |||||||||| Capvaxive (pneumococcal 21-valent conjugate vaccine) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion, Pneumococcal vaccines: STRIDE-8: Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (clinicaltrials.gov) - Feb 28, 2024
P3, N=518, Completed,
Efforts to improve vaccination rates in socially vulnerable areas have the potential to decrease the clinical and economic burden of pneumococcal disease and improve public health. Active, not recruiting --> Completed
- |||||||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date: MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - Dec 21, 2023
P=N/A, N=45, Recruiting,
It appears more critical to focus on maximising the initial vaccine response, which is known to be diminished in this patient population. Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
Enrollment open: Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 25, 2023
P2, N=70, Recruiting,
Multiplexed assessment of anti-PnPS and anti-protein responses combined with immunoglobulin quantification provides useful clinical information to support PID diagnosis. Not yet recruiting --> Recruiting
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Clinical, P3 data, Journal: A phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM). (Pubmed Central) - Oct 22, 2023
P3
Study results support the use of V114 in allo-HCT recipients. Clinical Trials Registration.?clinicaltrials.gov (NCT03565900) and European Union at EudraCT 2018-000066-11.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer, Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) - Study Update (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4259;
Vaccine uptake in women with SLE was subpar for most of the adult vaccines recommended for immunosuppressed persons. A gap exists with respect to vaccination for HPV, Pneumococcus (Prevnar13, Pneumovax 23), Tdap, Shingrix
- |||||||||| Capvaxive (pneumococcal 21-valent conjugate vaccine) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed, Pneumococcal vaccines: STRIDE-8: Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (clinicaltrials.gov) - Aug 24, 2023
P3, N=500, Active, not recruiting,
A gap exists with respect to vaccination for HPV, Pneumococcus (Prevnar13, Pneumovax 23), Tdap, Shingrix Recruiting --> Active, not recruiting
|
